Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position

With a focus on innovative oral therapies, Structure Therapeutics aims to address large patient populations underserved by current treatment options, positioning itself as a differentiated player in the global biopharmaceutical landscape.Structure Therapeutics is a clinical-stage biotechnology company specializing in the development of oral small molecule therapeutics for chronic diseases with significant unmet need. The company leverages expertise in G-protein-coupled receptor (GPCR) biology to advance a p ...